Business briefs: Everyday Health, Novo Nordisk

Share this article:

Everyday Health said advertising and sponsorship revenue grew 24% last year and that revenue from their top 20 advertisers grew 28%. The health portal said the number of registered consumer users rose to more than 55 million while visits to operated properties grew by 30%. Enhancements to MedPage Today helped bump physician/HCP numbers up 41% and aided an 18% rise in visits overall. Everyday Health launched its food platform and weekly TV series Recipe Rehab—the first YouTube-to-TV show—on ABC last year, and also acquired EQAL, which manages digital content for health and wellness brands and celebs, while expanding their blue-chip investor pool to include Silver Lake Waterman Fund. CEO Ben Wolin forecast “strong double-digit revenue growth” for 2013.

Novo Nordisk received a CRL from the FDA concerning Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). The CRL said neither drug could be approved in its current form. In the letter, the regulatory body cited a need for additional trials on cardiovascular safety. Novo Nordisk said in a statement they would not have that data prepared for resubmission in 2013. In November of last year, a FDA Advisory committee voted 8:4 to in favor of approval of degludec, with a unanimous decision reached by the panel that Novo should perform a larger clinical trial to examine whether the cardiovascular side effects are a real risk.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions